ODE IV Director Murphy will work on pediatric labeling initiative when she joins FDA March 1.
Executive Summary
ODE IV DIRECTOR MURPHY WILL FOCUS ON PEDIATRIC LABELING initiatives and development of a list of drugs that require pediatric clinical data as specified in the FDA Modernization Act. Dianne Murphy, MD, will assume directorship of the Center for Drug Evaluation and Research's Office of Drug Evaluation IV, which comprises the divisions of anti-viral and anti-infective drugs, on March 1. Murphy is the chief of general pediatrics at the University of Florida Health Science Center in Jacksonville.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth